TD Asset Management Inc Increases Stock Position in Arcellx, Inc. $ACLX

TD Asset Management Inc increased its stake in Arcellx, Inc. (NASDAQ:ACLX) by 124.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 232,708 shares of the company’s stock after buying an additional 129,248 shares during the period. TD Asset Management Inc’s holdings in Arcellx were worth $19,105,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Arcellx by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company’s stock valued at $1,893,000 after acquiring an additional 1,390 shares during the period. Empowered Funds LLC purchased a new stake in shares of Arcellx during the 1st quarter valued at about $1,768,000. Intech Investment Management LLC lifted its stake in shares of Arcellx by 27.7% in the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company’s stock worth $1,441,000 after purchasing an additional 4,760 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of Arcellx by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 8,883 shares of the company’s stock worth $585,000 after buying an additional 151 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Arcellx during the second quarter valued at approximately $563,000. 96.03% of the stock is owned by institutional investors.

Arcellx Price Performance

Shares of ACLX opened at $113.79 on Friday. Arcellx, Inc. has a 1 year low of $47.86 and a 1 year high of $114.26. The company has a 50 day simple moving average of $71.81 and a two-hundred day simple moving average of $76.25. The firm has a market cap of $6.58 billion, a P/E ratio of -28.95 and a beta of 0.36.

Insiders Place Their Bets

In related news, insider Christopher Heery sold 5,882 shares of the stock in a transaction that occurred on Wednesday, January 14th. The stock was sold at an average price of $68.51, for a total transaction of $402,975.82. Following the completion of the transaction, the insider directly owned 23,749 shares of the company’s stock, valued at approximately $1,627,043.99. This represents a 19.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rami Elghandour sold 89,916 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $113.92, for a total value of $10,243,230.72. Following the transaction, the insider owned 276,051 shares of the company’s stock, valued at $31,447,729.92. This represents a 24.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 109,366 shares of company stock worth $11,526,708. 8.35% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ACLX has been the topic of several analyst reports. Citigroup cut shares of Arcellx from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $110.00 to $115.00 in a research note on Tuesday, February 24th. HC Wainwright downgraded Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 target price on the stock. in a research report on Monday, February 23rd. Truist Financial cut Arcellx from a “buy” rating to a “hold” rating and reduced their price target for the stock from $134.00 to $120.00 in a research report on Monday, February 23rd. Canaccord Genuity Group set a $115.00 price objective on Arcellx in a research report on Monday, February 23rd. Finally, Guggenheim downgraded Arcellx from a “buy” rating to a “neutral” rating and cut their price objective for the company from $120.00 to $115.00 in a research note on Wednesday. One research analyst has rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $111.87.

Arcellx News Summary

Here are the key news stories impacting Arcellx this week:

• Neutral Sentiment: Reported short-interest data shows zero shares and a 0.0 days-to-cover figure for late February; this looks like a data or reporting anomaly rather than a meaningful change in market positioning — monitor for corrected filings or confirmations from exchanges.
• Neutral Sentiment: HC Wainwright published an FY2030 earnings forecast for Arcellx; long-range model updates can influence valuation assumptions but are less likely to move the stock immediately than near-term operational news. FY2030 Earnings Forecast for Arcellx Issued By HC Wainwright
• Neutral Sentiment: Market commentary pieces (example: “Is It Too Late To Consider Arcellx…”) are evaluating the recent run-up and valuation; these are background reads that may sway retail interest but do not constitute new company fundamentals. Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge?
• Negative Sentiment: Insider selling: Director Rami Elghandour sold 89,916 shares at ~$113.92 (≈$10.24M), cutting his stake by ~24.6%. Large insider sales at current levels can weigh on sentiment, especially after a recent price run. SEC Filing
• Negative Sentiment: Quarterly results: ACLX reported EPS of ($1.01), matching consensus, but revenue was $1.65M vs. expectations of $13.4M — a sizable revenue shortfall that highlights execution or timing risk and likely increases near-term volatility and downside pressure.
• Negative Sentiment: Analyst actions: UBS downgraded the stock, and both Robert W. Baird and Canaccord Genuity moved ACLX to “Hold” — multiple downward analyst moves reduce buy-side momentum and can trigger short-term selling. UBS downgrades Arcellx (ACLX) Cut to Hold at Robert W. Baird Cut to Hold at Canaccord Genuity Group

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.